Impax Laboratories, Inc. (NASDAQ:IPXL) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 7th. Analysts expect Impax Laboratories to post earnings of $0.20 per share for the quarter. Impax Laboratories has set its FY17 guidance at $0.55-0.70 EPS.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The business had revenue of $202.08 million during the quarter, compared to the consensus estimate of $195.62 million. During the same period in the prior year, the business posted $0.21 earnings per share. Impax Laboratories’s revenue was up 17.1% compared to the same quarter last year. On average, analysts expect Impax Laboratories to post $0.7 EPS for the current fiscal year and $1.06 EPS for the next fiscal year.

Shares of Impax Laboratories, Inc. (NASDAQ IPXL) opened at 18.50 on Tuesday. The stock’s 50 day moving average price is $21.10 and its 200 day moving average price is $17.74. Impax Laboratories, Inc. has a one year low of $7.75 and a one year high of $25.70. The stock’s market capitalization is $1.33 billion.

Several research analysts have weighed in on the company. Cantor Fitzgerald lifted their target price on Impax Laboratories from $20.00 to $25.00 and gave the stock an “overweight” rating in a report on Monday, September 11th. Zacks Investment Research upgraded Impax Laboratories from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Tuesday, July 11th. Citigroup Inc. upped their target price on Impax Laboratories to $23.00 and gave the stock a “buy” rating in a report on Tuesday, September 19th. BTIG Research reiterated a “buy” rating and set a $27.00 target price (up previously from $20.00) on shares of Impax Laboratories in a report on Saturday, September 23rd. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $23.00 target price on shares of Impax Laboratories in a report on Tuesday, September 19th. Five equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the stock. Impax Laboratories currently has an average rating of “Hold” and an average target price of $19.14.

TRADEMARK VIOLATION NOTICE: “Impax Laboratories, Inc. (IPXL) Scheduled to Post Earnings on Tuesday” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/31/impax-laboratories-inc-ipxl-scheduled-to-post-earnings-on-tuesday.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Earnings History for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.